Form 4: 4D Molecular Therapeutics Director Exercises Options

4D Molecular Therapeutics Director Charles Theuer exercised options to acquire 9,333 shares of common stock at $1.14 per share.

Summary

• Charles Theuer, a Director at 4D Molecular Therapeutics, Inc. (FDMT), executed a transaction involving the exercise of stock options.
• The transaction occurred on December 12, 2025.
• He acquired 9,333 shares of common stock at an exercise price of $1.14 per share.
• Following this transaction, Charles Theuer directly beneficially owns 41,684 shares of 4D Molecular Therapeutics common stock.
• The stock options exercised were fully vested.

Sentiment

Score: 6

Explanation: The exercise of stock options by a director is a routine compensation event that generally indicates a neutral to slightly positive sentiment, as it reflects the director's decision to convert options into shares, implying confidence at the exercise price.

Positives

• A director increasing their direct ownership in the company can be interpreted as a positive signal of confidence in the company's future prospects and valuation.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the director's increased direct ownership as a sign of continued commitment and confidence in the company's value.

Key Dates

Recommendation

This Form 4 filing details a routine exercise of stock options by a director, which is a standard compensation event. While it increases the director's direct ownership and can be seen as a minor positive signal of confidence, it does not present new material information or significant strategic shifts that would warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

4D Molecular Therapeutics, FDMT, Charles Theuer, Insider Transaction, Stock Option Exercise, Director, Beneficial Ownership